Maven Securities LTD Otonomy, Inc. Transaction History

Maven Securities LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$1.22 - $2.2 $342,802 - $618,169	-280,986 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$2.06 - $2.67 $158,311 - $205,189	76,850 Added 37.65%	280,986 $655,000
Q1 2021 May 17, 2021	BUY	$2.49 - $6.23 $383,798 - $960,267	154,136 Added 308.27%	204,136 $512,000
Q4 2020 Feb 12, 2021	SELL	$3.48 - $6.47 $495,426 - $921,095	-142,364 Reduced 74.01%	50,000 $324,000
Q3 2020 Nov 13, 2020	BUY	$3.16 - $4.36 $607,870 - $838,707	192,364 New	192,364 $756,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Maven Securities LTD, based on Form 13F filings with the SEC.

Stay updated on Maven Securities LTD with notifications on news.